This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Focus on Women's Mental Health

Exposure to Mirtazapine During Pregnancy: A Prospective, Comparative Study of Birth Outcomes

Josephine Djulus, MD; Gideon Koren, MD; Thomas R. Einarson, PhD; Lynda Wilton, PhD; Saad Shakir, MD; Orna Diav-Citrin, MD; Deborah Kennedy, MD; Sharon Voyer Lavigne, MSc; Marco De Santis, MD; and Adrienne Einarson, RN

Published: August 15, 2006

Article Abstract

Background: Mirtazapine is a novelpiperazinoazepine antidepressant, unrelated to any known class ofantidepressants. Currently, apart from a few case reports andcase series in the literature, there are no studies evaluatingthe safety of this drug during pregnancy.

Objective: To determine whether mirtazapineincreases the risk for major malformations in newborns when usedby pregnant women.

Method: The study design was prospective, with 2comparison groups: disease-matched pregnant women diagnosed withdepression taking other antidepressants and pregnant womenexposed to nonteratogens. The primary outcome was majormalformations in neonates; secondary endpoints includedspontaneous abortions, therapeutic abortions, gestational age atbirth, and mean birth weight. Women were recruited from 5teratogen information services in Toronto, Canada; Farmington,Conn., U.S.A.; Jerusalem, Israel; Rome, Italy; Sydney, Australia;and from the Drug Safety Research Unit in Southampton, UnitedKingdom. Women were recruited into the study from June 2002 toAugust 2005.

Results: We were able to follow 104 pregnancyoutcomes in each drug group. There were 77 live births, 1stillbirth, 20 spontaneous abortions, 6 therapeutic abortions,and 2 major malformations in the mirtazapine group. The mean ± SDbirth weight was 3335 ± 654g and the mean ± SD gestational age atdelivery was 38.9 ± 2.5 weeks. Most (95%) of the women took mirtazapine in the first trimester, but only 25% of the womentook it throughout pregnancy. The differences among the 3 groupswere in the rate of spontaneous abortions, which was higher inboth antidepressant groups (19% in the mirtazapine group and 17%in the other antidepressant group) than in the nonteratogen group(11%), but none of the differences were statisticallysignificant. The rate of preterm births (prior to 37 weeks’gestation) was also higher in the mirtazapine group (10%) and inthe other antidepressant group (7%) than in the nonteratogengroup (2%). The difference was statistically significant betweenthe mirtazapine group and the nonteratogen group (p = .04).

Conclusion: Mirtazapine does not appear toincrease the baseline rate of major malformations of 1% to 3%.However, the higher number of spontaneous abortions in theantidepressant groups confirms the higher rates of spontaneousabortions in pregnant women taking antidepressant medicationsfound in previous studies.

Volume: 67

Quick Links: Populations , Women

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression

Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived...

Read More...